A look at our solutions

C

Caring for skin and hair, promoting oral hygiene

C

Caring for each person means first of all combining our expertise in dermatology, dentistry and cosmetology to create targeted dermo-cosmetics and oral hygiene products that enhance the daily lives of our patients and consumers. These products are designed and developed with the help of health care professionals. A-Derma’s EXOMEGA ALLERGO range offers, for example, the first care products specially created for atopic and allergic patients, thanks in particular to the ultra-tolerability of our preservative-free Sterile Cosmetics technology. Pierre Fabre Oral Care is pursuing its drive for the medical development of dental accessories, with a comparative method to assess the effectiveness of toothbrushes on the removal of dental plaque using a robot that perfectly reproduces brushing movements.This protocol has confirmed the superiority of INAVA/ELGYDIUM Clinic toothbrushes compared to the main competitors*.

*Over 15% of dental plaque removed with the 15/100 reference.

T

Treating skin diseases

C

Caring for each person means developing solutions for dermatological diseases, including the rarest. Pierre Fabre’s products treat common skin conditions, such as atopic dermatitis, psoriasis and acne, and since 2022 actinic keratosis, a pre-cancerous skin lesion located mainly on the face caused by regular and excessive sun exposure.

The Group is also dedicated to the development of new treatments for rare dermatological diseases, such as severe infantile hemangioma and ectodermal dysplasia (XLHED). Dermatology is the specialty that covers the greatest number of rare pathologies in the world.

T

Treating cancer

C

Caring for each person means helping to prevent and fight cancer. Pierre Fabre Laboratories has been conducting research and development in oncology for over 40 years. Pierre Fabre currently proposes solutions for preventing, treating and fighting melanoma and colorectal, breast and lung cancer. Our Transformation plan has also prioritized the development of our portfolio of oncological products. Our R&D efforts have focused on targeted therapies, in “niche” and orphan indications.

To accelerate innovation and meet the most critical needs, Pierre Fabre has adopted a high-added-value partnership approach. Our partnership initiated with Array and continued with the pharmaceutical laboratory Pfizer has enabled the development and marketing of a targeted treatment in onco-dermatology. New indications, such as lung cancer, are also under development.

Similarly, Pierre Fabre’s partnership with Puma Biotechnology is giving people with HER2-positive breast cancer access to innovative treatment throughout Europe and in other regions, including China, and Europe.

T

Treating chronic diseases

C

Caring for each person means helping to improve treatment of chronic diseases. The prescription drugs marketed by the Pierre Fabre Group cover a broad spectrum of such pathologies and help to improve the lives of patients in many therapeutic areas, including urology, women’s health and rheumatology.

In 2022, Pierre Fabre acquired the rights to market a treatment for overactive bladder in Europe as part of a licensing agreement with Urovant Sciences. This clinical condition manifests as involuntary muscle contractions of the bladder and can be incapacitating.

T

Treating everyday ailments

C

Caring for each person means supporting each person in their daily lives. To this end, Pierre Fabre offers a wide range of family health treatments, available with or without a medical prescription, for sore throats, smoking cessation, urinary infections and even painful periods.

A new product for preventing vitamin D deficiency will soon be launched in several European countries under a licensing agreement signed in 2022 with the Belgian company Nutrimed. Pierre Fabre Laboratories are also France’s leading laboratory for products designed to help people quit smoking and thus prevent lung cancer.